Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/30/-0001 |
| Start Date: | October 2010 |
| End Date: | December 2013 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
An Exploratory Phase 2, Randomized, Double-Blind, Multicenter Study To Assess The Effects Of Tofacitinib (CP-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naïve Subjects With Early Active Rheumatoid Arthritis
Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early
rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate
naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed
by magnetic resonance imaging, x-rays and by standard clinical assessment.
Inclusion Criteria:
- Adult patients with moderate to severe early rheumatoid arthritis (< 2 years) who are
methotrexate and biologic disease modifying antirheumatic drug naive.
Exclusion Criteria:
- Pregnant or lactating patients;
- Patients with renal or hepatic impairment or other severe or progressing disease;
- Patients with contraindication to magnetic resonance imaging with gadolinium
contrast.
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials